Last reviewed · How we verify
PSILOCIN
At a glance
| Generic name | PSILOCIN |
|---|---|
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (PHASE3)
- Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (PHASE1)
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (PHASE3)
- Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (PHASE3)
- Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD (PHASE1)
- Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder (PHASE2)
- Precision Functional Brain Mapping in Psilocybin (EARLY_PHASE1)
- A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PSILOCIN CI brief — competitive landscape report
- PSILOCIN updates RSS · CI watch RSS